Predictors of achieving HbA1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study

Current Medical Research and Opinion

Volumn 29, Issue 6, 2013, Pages 601-609

  Valensi, Paul ^a   Shaban, Joseph ^b   Benroubi, Marian ^c   Kawamori, Ryuzo ^d   Borzì, Vito ^e   Shah, Siddharth ^f   Wenying, Yang ^g   Prusty, Vinay ^h   Hansen, Jes B ^h   Gumprecht, Janusz ⁱ  

^a UNIVERSITÉ PARIS 13   (France)

^b WINDSOR REGIONAL HOSPITAL   (Canada)

^c KAT HOSPITAL   (Greece)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF CATANIA   (Italy)

^f Bhatia Hospital   (India)

^g CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^h NOVO NORDISK A S   (Denmark)

ⁱ MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Biphasic insulin aspart 30; Clinical inertia; Insulin therapy; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; HEMOGLOBIN A1C; INSULIN ASPART; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN ASPART, INSULIN ASPART PROTAMINE DRUG COMBINATION 30:70; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE DURATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; PREDICTOR VARIABLE; ANALYSIS; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; MIDDLE AGED; TREATMENT OUTCOME;

BIPHASIC INSULINS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, ISOPHANE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84877285513     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.786692     Document Type: Article

References (38)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
2. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
3. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005
4. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61
5. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets Poor adherence versus lack of treatment intensification. Gen Intern Med 2008;23:588-94
6. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
7. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
8. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med 2009;22:453-8
9. Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2007;29:1236-53
10. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010;4(Suppl 1):S11-18
11. Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better Diabetes Care 2009;32:1789-95
12. Davidson MB. Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 2005;28:222-4
13. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-59
14. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28
15. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
16. Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399-403
17. Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002;25:883-8
18. Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clin Ther 2006;31:1641-51
19. Warren ML, Conway MJ, Klaff LJ, et al. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004;66:23-9
20. Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-94
21. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
22. Liebl A, Prager R, Binz K, et al.; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45-52
23. Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of insulin analogs in achieving the hemoglobin A1c target of 57% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 2011;34: 510-17
24. Valensi P, Benroubi M, Borzi V, et al.; IMPROVE Study Group Expert Panel. The IMPROVE study-a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 2008;62:1809-19
25. Yang WY, Benroubi M, Borzi V, et al.; IMPROVE Study Group Expert Panel. Improved glycaemic control with BIAsp 30 in insulin-naive type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Curr Med Res Opin 2009;25:2643-54
26. Gumprecht J, Benroubi M, Borzi V, et al.; IMPROVE Study Group Expert Panel. Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study. Int J Clin Pract 2009;63:966-72
27. Shah S, Benroubi M, Borzi V, et al.; IMPROVE Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. Int J Clin Pract 2009;63:574-82
28. Velojic-Golubovic M, Mikic D, Pesic M, et al. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Invest 2009;32:23-7
29. DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010;27:309-17
30. Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target57% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes Metab 2012;14:228-33
31. Davis TM, Brown SG, Jacobs IG, et al. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab 2010;95:2240-7
32. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
33. Akram K, Pedersen-Bjergaard U, Carstensen B, et al. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a crosssectional survey. Diabet Med 2006;23:750-6
34. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247-56
35. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 2010;33:733-5
36. Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview or fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 2011;14:646-55
37. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes 2006;24:115-21
38. Lüddeke HJ, Sreenan S, Aczel S, et al.; PREDICTIVE study group. PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428-34